The FIRST and ONLY event focusing on MENA (Middle East and North Africa) as well as CIS (Commonwealth of Independent States) vaccine industry.

There will be a strong focus on partnerships, novel research and development as well as state of the art technical solutions.

**DISTINGUISHED PANEL OF SPEAKERS**

- **Dr. Ahmed Emara, CEO & Managing Director**, ReAya Holding (Holding company of AraBio), Saudi Arabia
- **Dr. Stanley C. Erick**, Chief Executive Officer, Novavax Inc, USA
- **Dr. Mutia Topal**, Managing Director, Kayman Iac, Turkey
- **Prof. Dr. Bulent Gumusel**, Dean of Pharmacy, Faculty of Pharmacy, Ankara University - Ankara, Turkey
- **Dr. Kutub Mahmood**, Scientific Director, Polio Vaccine Development Project, PATH, USA
- **Prof. Sayadyan Khachatik**, CEO, NT Pharma, Russia
- **Mr. K. V. Balasubramanium**, Managing Director, Indian Immunologicals, India
- **Ms. Eman Aly**, Vice President Middle East & North Africa, Sanofi Pasteur, Turkey
- **Prof. Dr. Mustafa Hayemustafaoglu**, Department of Pediatrics, Faculty of Medicine, Uludag University, Turkey
- **Mr. K. V. Balasubramanium**, Managing Director, Indian Immunologicals, India
- **Ms. Eman Aly**, Vice President Middle East & North Africa, Sanofi Pasteur, Turkey
- **Dr. Daniel D. Adams**, Executive Chairman and Global Head of Business Development, Protein Sciences Corporation, USA
- **Beril Tazcanli**, Quality Group Director, Mefar Ilac, Turkey
- **Syedah Maria Bokhari**, Regional Vaccines Commercial Head - MENA & CIS, GSK, Turkey
- **Dr. Daniel D. Adams**, Executive Chairman and Global Head of Business Development, Protein Sciences Corporation, USA
- **Beril Tazcanli**, Quality Group Director, Mefar Ilac, Turkey
- **Syedah Maria Bokhari**, Regional Vaccines Commercial Head - MENA & CIS, GSK, Turkey
- **Dr. Reinhard Glück**, Chief Scientific Officer, Zydus Cadila, India

**Why you should attend Vaccine World MENA & CIS 2014?**

- Learn about the latest trends in vaccine MENA and CIS industry
- Network with high level decision makers and KOLs in MENA and CIS
- Learn good manufacturing practices and manufacturing excellence to conform to international standards
- Discuss latest R&D and strategies for vaccine innovations
- Discuss how to accelerate vaccine R&D through interesting case studies and showcases

Register before 1 AUG and Save up to 600 USD
It’s my sincere pleasure to welcome you to the inaugural of Vaccine World Summit MENA and CIS 2014, which will be held in Istanbul, Turkey from 18th – 20th November 2014. This event organized by IMAPAC will bring around 20 world class speakers to present and share their experiences and knowledge in Istanbul where two continents meet each other. Together, we will have a great opportunity to promote innovation and development for vaccines in MENA and CIS region so as to ensure adequate supply of high quality vaccines for our public.

Being a part of the vaccine industry gives each of us the ability to have a positive impact on the lives of millions of people that we will probably never meet. It is an honor and a pleasure to have the power to relieve the unnecessary suffering caused by infectious diseases and to perform a very significant service to the entire world.

While our work has already transformed many lives, we should not forget that over 9.5 million people die each year due to infectious diseases. Together we can improve this situation. This is why I encourage you to be part of the Vaccine World Summit, we welcome all public health professionals, NGOs, vaccine business leaders, academics and all other related stakeholders to be part of this global vaccine event.

This year we will focus on the latest success strategies for vaccines in MENA and CIS region, innovative partnership models, manufacturing technologies and novel research.

I am looking forward to seeing each and every one of you join us next November in Istanbul, Turkey. Let’s share and listen together so we can share exciting new ideas, stimulate growth of the vaccine industry and improve lives of people worldwide.

Yours sincerely,

Dr. O. Mutlu Topal
Managing Director,
Keymen Ilac,
Turkey;
Vaccine World MENA and CIS Summit 2014

EVENT AT A GLANCE

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>IMAPAC’S Welcoming Remarks</td>
<td>IMAPAC’S Welcoming Remarks</td>
<td>IMAPAC’S Welcoming Remarks</td>
</tr>
<tr>
<td>Chairman’s Opening Remarks</td>
<td>Chairman’s Opening Remarks</td>
<td>Chairman’s Opening Remarks</td>
</tr>
<tr>
<td><strong>Key Note CEO Plenary Session:</strong> Gain Insights into the CIS and MENA current market landscape through Key Opinion Leaders in the Industry</td>
<td><strong>New Vaccines, New Opportunities:</strong> Look into Novel Research &amp; Development of Vaccines for the MENA and CIS Region (ex: Kalar Azar Disease, Hepatitis C)</td>
<td><strong>Vaccine Supply Chain Dialogue:</strong> Meeting Vaccine Demand for EPIs and UPIs, Working with Government, NGOs and Non-Profit Organizations, Forecasting and Managing Supply and State of the art cold chain solutions</td>
</tr>
<tr>
<td>Speed Networking and Morning Refreshments</td>
<td>Morning Refreshments</td>
<td>Chairman’s Closing Remarks</td>
</tr>
<tr>
<td><strong>New Vaccines, New Opportunities:</strong> Look into Novel Research &amp; Development of Vaccines for the MENA and CIS Region (ex: Collaborating with Academia, Polio and Influenza vaccines)</td>
<td>Networking Lunch and Technical Seminars</td>
<td>Networking Lunch and Technical Seminars</td>
</tr>
<tr>
<td>IMAPAC’S Welcoming Remarks</td>
<td>Chairman’s Opening Remarks</td>
<td>Chairman’s Closing Remarks</td>
</tr>
<tr>
<td><strong>Making inroads into MENA and CIS Vaccine Market:</strong> Overview of Regulatory Framework in MENA and CIS Region and Market Access, Entry Strategies</td>
<td><strong>New Vaccines, New Opportunities:</strong> Look into Novel Research &amp; Development of Vaccines for the MENA and CIS Region (ex: MERS and Meningococcal vaccines)</td>
<td><strong>Round Table Discussions:</strong> What factors to consider in developing a Robust and Innovation driven pipeline</td>
</tr>
<tr>
<td>Afternoon Refreshments &amp; Exhibition Visit</td>
<td>Afternoon Refreshments and Exhibition Visit</td>
<td>Chairman’s Closing Remarks</td>
</tr>
<tr>
<td><strong>Round Table Discussions:</strong> Looking into current partnership models, key considerations before entering the market</td>
<td><strong>Vaccine Scale Up and Process Design Strategies:</strong> Optimizing cell culture, Cost - benefit analysis of Single use systems Fill &amp; Finish</td>
<td><strong>Round Table Discussions:</strong> Manufacturing economics and cost efficient processing</td>
</tr>
<tr>
<td>Chairman’s Closing Remarks</td>
<td>Chairman’s Closing Remarks</td>
<td>Chairman’s Closing Remarks</td>
</tr>
</tbody>
</table>

Register at www.imapac.com or email Cecilia at cecilia.wong@imapac.com or call her at +65 6493 2093
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00</td>
<td>Registration commences</td>
</tr>
<tr>
<td>13:30</td>
<td><strong>Overview of Regulatory Framework in MENA and CIS Region and Market Access, Entry Strategies</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Making inroads into the MENA market: Current trends and partnership models in the MENA Vaccine market</strong></td>
</tr>
<tr>
<td></td>
<td>• Successful partnership models and what make such partnerships work?</td>
</tr>
<tr>
<td></td>
<td>• Utilizing IP as a tool to develop, sustain and protect partnerships</td>
</tr>
<tr>
<td></td>
<td>• Overcoming regulatory barriers via partnerships</td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Ahmed Emara</strong>, <strong>CEO &amp; Managing Director</strong>, ReAya Holding, <strong>Saudi Arabia</strong></td>
</tr>
<tr>
<td>13:55</td>
<td><strong>Panel Discussion</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Streamlining vaccine regulatory pathway to meet changing demand</strong></td>
</tr>
<tr>
<td></td>
<td>• Overcoming challenges in Implementing sustainable vaccine development programs in developing countries</td>
</tr>
<tr>
<td></td>
<td>• Role of partnerships in policy strategizing and implementation.</td>
</tr>
<tr>
<td></td>
<td>• Addressing the gaps in understanding of regulations</td>
</tr>
<tr>
<td></td>
<td><strong>Mr. Cagdas Balci</strong>, Strategic Planning and Marketing Sales Operations Director, Novartis, Turkey</td>
</tr>
<tr>
<td></td>
<td><strong>Invitation to:</strong> <strong>Prof. Dr. Secil Ozkan</strong>, Director of Public Health Directorate, Ankara, Turkey</td>
</tr>
<tr>
<td></td>
<td><strong>Ms. Gihan Hamdy El-sisi</strong>, Team Leader of HPA, Central Administration for Pharmaceutical Affairs, Ministry of Health and Population, Egypt</td>
</tr>
<tr>
<td>14:35</td>
<td><strong>Afternoon Refreshments and Speed Networking</strong></td>
</tr>
<tr>
<td>15:05</td>
<td><strong>Testing commercial-ability of introducing vaccines into MENA and CIS market: MNC Perspective</strong></td>
</tr>
<tr>
<td></td>
<td>• Challenges and opportunities in the MENA and CIS market</td>
</tr>
<tr>
<td></td>
<td>• Analysis of competitiveness and partnership opportunities for the CIS region</td>
</tr>
<tr>
<td></td>
<td><strong>Ms. Syedah Maria Bokhari</strong>, Regional Vaccines Commercial Head - Middle East North Africa &amp; CIS, GSK, Turkey</td>
</tr>
<tr>
<td>15:35</td>
<td><strong>Establishing and managing long distance partnerships</strong></td>
</tr>
<tr>
<td></td>
<td>• Analysis of competitiveness for the MENA and CIS region</td>
</tr>
<tr>
<td></td>
<td>• Criteria that is looked into before entering a particular market</td>
</tr>
<tr>
<td></td>
<td>• Case studies</td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Bernd Eisele</strong>, Chief Executive Officer, Vakzine Projekt Management, Germany</td>
</tr>
<tr>
<td>16:00</td>
<td><strong>Roundtable Discussions</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Roundtable 1</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Entering Emerging MENA and CIS Market</strong></td>
</tr>
<tr>
<td></td>
<td>• Opportunities, Major challenges and how to avoid common pitfalls</td>
</tr>
<tr>
<td></td>
<td>• Commercial and operational considerations of successfully navigating the evolving regulatory framework</td>
</tr>
<tr>
<td>16:50</td>
<td><strong>Cocktail Reception</strong></td>
</tr>
</tbody>
</table>
## Conference Day 1  19 November 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:15</td>
<td>Registration Commences</td>
</tr>
<tr>
<td>8:55</td>
<td>IMAPAC’s Welcome Remarks</td>
</tr>
<tr>
<td>9:00</td>
<td>Chairman’s Opening Remarks</td>
</tr>
</tbody>
</table>

### Key Note Panel Discussion

**9:10 Keynote Roundtable**

**Gain Insights into the CIS and MENA current market landscape through Key Opinion Leaders in the Industry**

- Overview of MENA and CIS Vaccine Market: Trends and opportunities
- Look into growth opportunities for this region
- How to position your company in the next 5 years and analyzing what need to be done to achieve continuous growth in MENA and CIS vaccine industry

**Confirmed Panellists:**
- Dr. O. Mutlu Topal, Managing Director, Keymen Ilac, Turkey
- Dr. Ahmed Emara, CEO & Managing Director at ReAya Holding, Saudi Arabia

**Invited Panellists:**
- Dr. Hechmi Louzir, Director General of Institut Pasteur de Tunis, Tunisia
- Professor Arkady Nekrasoy, CEO, NPO Petrovax Pharma, Russia

### New Vaccines, New Opportunities: Focus on Vaccine Research and Development in MENA and CIS Region

**10:00 Morning Refreshments and Speed Networking**

### Promoting R&D in the MENA region by collaborating with Academia

**10:45**

- Look into Novel Research & Development of Vaccines for the MENA and CIS Region
- Case Study

**Prof. Dr. Bulent Gumusel, Dean of Pharmacy Faculty, Hacettepe University - Ankara, Turkey**

### Polio: Battling a versatile foe

**11:10**

- Advancement of IPV vaccine development
- Eradication of polio in the MENA region? What needs to be done in the coming years and role of regional vaccine manufactures and distributors

**Dr. Kutub Mahmood, Scientific Director, Polio Vaccine Development Project, PATH, USA**

### Vaccines for the Future Session I – Focus on Influenza Vaccine

**11:35**

- Importance of Influenza Vaccination for the Middle East and CIS region
- Look into Novel Research & Development of Vaccines for the Influenza
- Case Study: AdeVac-Flu

**Prof. Saiadian Khachik, CEO Abiolek Company & Director of Science, NTpharma, Russia**

### Lunch Networking Session

**12:00**

### Vaccines for the Future Session I – Focus on MERS Vaccine

**13:00**

- Importance of MERS Vaccination for the Middle East region
- Look into Novel Research & Development of Vaccines for the MERS
- Case Study: nanoparticle vaccine for MERS-CoV by Novavax

**Dr. Stanley C.Erck, Chief Executive Officer, Novavax Inc, USA**

### Vaccines for the Future Session II – Importance of Meningococcal Vaccines

**13:25**

- Importance and of Meningococcal vaccination in the Middle Eastern region

**Prof. Dr. Mustafa Hacimustafaoğlu, Department of Pediatrics, Faculty of Medicine, Uludag University, Turkey**

### Round Table Discussions

**13:50**

- What factors to consider in developing a Robust and Innovation driven pipeline
  - How to ensure that your research is economically viable in the vaccine industry
  - Collaborative advantages of research and manufacturer partnerships
  - Co-development partnerships and Technology Transfers: helping you to take your product to masses

### Prayer Break and Afternoon Refreshment

**14:25**

### Vaccine Scale Up and Process Design Strategies

**14:45**

- Evaluation of use of Single Use Technology
  - Pros and cons of using disposable systems in upstream and downstream, small and large-scale processing
  - Managing single use technology in clinical and commercial development; scaling up and down
  - Testing and risk management of extractable and leachable in single use bioreactors
  - Reserved for Technology Solution Provider

**15:10**

- The right attitude and equipment to ensure vaccine of the highest quality
  - Implementing QBD in the vaccine development cycle
  - Choosing the best suited technological systems for a low cost high volume production
  - Case Study

**Dr. Reinhard Glück, CSO, Zydus Cadila, India**
15:35 | Optimizing Cell Culture  
- Methods and compositions for increasing longevity and protein yield from a cell culture  
- How to improve process consistency  
- Analysing transfer and scalability data for cell culture  
*Reserved for Technology Solution Provider*

16:00 | Vaccine manufacturing capabilities, challenges and opportunities in the MENA region  
*Mrs. Beril Tezcanli, Quality Group Director, Mefar Ilac, Turkey*

### Round Table Discussions
16:25 | Manufacturing economics and cost efficient processing  
- Designing downstream facilitates to align with upstream manufacturing strategies  
- Cutting-edge automation, controls to increase downstream productivity  
- Economic analysis of facility utilization, cost vs. product yield & purity

16:50 | Chairman’s Closing Remarks

---

### CONFERENCE DAY 2 | 20 NOVEMBER 2014

8:30 | Registration Commences

9:00 | Chairman’s Opening Remarks

#### Best Practises and Manufacturing Economics

9:00 | **Trends & Challenges in Technical and Manufacturing Collaboration in MENA and CIS Region**  
- Identifying the right partner  
- Evaluating platform technology, therapeutic focus & geographical focus  
- Exploring manufacturing partnership structures: co-development, licensing opportunities & pitfalls to avoid  
*Dr. Daniel D. Adams, Executive Chairman and Global Head of Business Development, Protein Sciences Corporation, USA*

9:25 | **State of the art engineering solutions and flexible facility planning**  
- Alternative approaches to ensure maximum productivity for multiple product manufacturing in a single space  
- Automation technologies to improve productivity  
*Reserved for Technology solution provider*

9:50 | **Fill and Finish Strategies – should we outsource?**  
- Outsourcing fill and finish functions – advantages, disadvantages and cost benefit analysis  
- Challenges faced during fill and finish process and how to overcome them  
*Dr. O. Mutlu Topal, Managing Director, Keymen Ilac, Turkey*

#### Vaccine Supply Chain Dialogue

10:15 | Morning Refreshments

10:45 | **Forecasting vaccine demand & supply in MENA and how does it affect vaccine manufacturers & distributors**  
- Price point pressures along the vaccine manufacturing process and how it impede growth of new vaccine development  
- Role of NGOs: Pricing concerns in ensuring a sufficient vaccines supply  
- Possible new initiatives or programs that can bridge supply gap  
*Ms. Eman Ali, Vice President, Business Unit Head, Turkey, Middle East and North Africa, Sanofi Pasteur, Turkey*

11:10 | **Thermal stability of conjugate vaccines: the advantages of being able to take vaccines outside the cold chain**  
- MenAfriVac case study  
*Dr. Marc LaForce, Director - Technical Services, Serum Institute of India, USA*

11:35 | **State of the art Vaccine Cold Chain Management**  
- Challenges of cold chain management in the MENA region  
- Meeting temperature sensitive requirements  
- Utilizing novel technology and quality management systems to reduce spoilage  
*Reserved for Technology solution provider*

12:00 | Chairman’s Closing Remarks

12:10 | Lunch Networking Sessions

14:00 | End of Conference Proceedings
WHY SHOULD YOU SPONSOR?

Vaccine World MENA & CIS 2014 will provide commercial organizations with the opportunity to:

- Educate the market about what you offer
- Position yourselves as leaders in your field alongside key industry figures
- Raise brand awareness
- Enjoy the option of privately arranged meetings and consultations with selected potential clients
- Hold face-to-face meetings with your target profile

PLUS! Book early to take advantage of the world-class marketing campaign!

- 50+ touch points over 9 months
- 20,000+ individual communications
- Integrated campaign featuring web, social media, email, press releases etc
- Partnerships with leading international publications & associations

For more information on sponsorship & exhibition opportunities, contact:

Vibhas Pahuja
Business Development Manager
+65 6493 1598
vibhas.pahuja@imapac.com

Organizations that previously attended our Vaccine events

- Abiolek LLC
- Bill and Melinda Gates Foundation
- Czech Embassy
- Embassy of Ukraine to the Russian Federation
- Etna Biotech
- Kerry
- Microgen Holding
- Ministry of Health of Russian Federation
- MOH. Ukraine
- Nanolek
- NewVac
- Novartis Vaccines and Diagnostics, Inc.
- NPO Petrovax Pharm
- PALL International Sarl
- Pharmaceutical Industry Review
- Protein Sciences Corporation
- Russian Academy of Sciences
- Saint-Petersburg Institute of Vaccines & Sera of the Russian FMBA
- IBC Nanotex
- PALL Eurasia LLC
- Sanofi Pasteur
- Sartorius ICR / Biohit LLC
- Selecta Biosciences
- SOTIO
- US Commercial Service
- Vaxine
- VisMederi-SRL
and many more

2013 Sponsors & Exhibitors:

Register at www.imapac.com or email Cecilia at cecilia.wong@imapac.com or call her at +65 6493 2093
REGISTRATION FORM

GENERAL PACKAGES & OFFER DEADLINES

<table>
<thead>
<tr>
<th>3 Day Conference Pass (18 - 20 November 2014)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOVERNMENT/ACADEMIC</td>
</tr>
<tr>
<td>VACCINE MANUFACTURERS FROM BRIC (BRAZIL, RUSSIA &amp; CIS, INDIA &amp; CHINA)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

The registration fee includes refreshments, lunch and full conference documentation.

The conference fee does not include hotel accommodation.

Special discounts & eligibility (Only one discount scheme is applicable. Call Cecilia at +65 6493 2093 to obtain your discount codes):

• ACADEMIC DISCOUNT: International academics, NGOs, government and non-profit representatives enjoy up to 40% off the usual conference pricing.
• INNER CIRCLE: Speaker referrals & professionals working in the same organization as our speakers are entitled to a 15% discount.
• PRIZE FREEZE: Clients of our sponsors & exhibitors can avail the first-tier price throughout the campaign, even after the deadline has passed!
• GROUP PACKAGES: Save 10% for 3 delegates & 20% for 5 delegates.
• PHARMACEUTICAL MANUFACTURERS ASSOCIATION OF TURKEY: Members are entitled to a 20% discount off General Pricing.

YOUR DETAILS

Name ___________________________ 
Job Title ___________________________ Organizational ___________________________
Address ___________________________ Country ___________________________
Tel ___________________________ Fax ___________________________
Email ___________________________
Your primary business ___________________________ 
Authorising Manager ___________________________ Authorising manager signature ___________________________
By signing and returning this form, you are accepting our terms and conditions.

PAYMENT DETAILS

Payment is due immediately upon receipt of this registration form if you pay by credit card or 3 working days after your receipt of payment notification. Non-credit card payment will incur an additional US$100 booking fee.

I want to pay _☐_ Credit Card _☐_ Non-credit card and add US$100 booking fee

Online credit card payment: Please register at: www.imapac.com/business_conference/vaccine-world-mena-and-cis-2014/pricing

Offline credit card payment: 
☐ Visa ☐ MasterCard ☐ American Express
Name on Card ___________________________ 
Card Number ___________________________ Expiry Date ___________________________
CVC Code ___________________________ Signature ___________________________

Bank transfer: Payment by bank transfer must quote delegate name and conference name. For bank details & swift code, it will be emailed to you as part of the invoice.

Cheque payment: Crossed cheque payable to IMAPAC Pte Ltd, and mail it in a sealed envelope to IMAPAC Pte Ltd, 100 Beach Road #16-09/13 Shaw Tower Singapore 189702

TERMS & CONDITIONS:

• Full payment is due upon registration if you pay by credit card, or 3 working days after receipt of invoice.
• Registration will not be confirmed until full payment has been received.
• Unpaid registration will be billed 50% of the registration fee if you do not attend the event. A copy of the conference documentation will be mailed to you.
• The registration fee includes refreshments, lunches, cocktails and full conference documentation. The conference fee does not include hotel accommodation.
• At the event you will receive a credit card guarantee for delegates without proof of payment.

CANCELLATION & SUBSTITUTION POLICY:

• Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit note to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee.
• A substitution from the same organisation can be made at any time in writing at no extra charge.
• In the event that IMAPAC cancels a conference, payments received at the cancellation date will be credited towards attendance at a future conference or in the event of postponement by IMAPAC, towards the rescheduled date.
• Credit notes remain valid for twelve months.

CHANGES TO CONFERENCE & AGENDA: IMAPAC reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers for an event. IMAPAC is not responsible for any loss or damage as a result of substitution, alteration, postponement or cancellation of an event due to causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

In the event that a conference is cancelled, IMAPAC is not liable for any costs incurred by delegates in connection with their attendance. Control to alter the content and timing of the programme, venue or the identity of the speakers without any liability to the delegates. Changes to the agenda will be updated on our website as soon as possible.

DATA PROTECTION: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to reputable third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: data@imapac.com.